MPM Oncology Impact Management »

Akebia Therapeutics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Akebia Therapeutics (AKBA) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Akebia Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Akebia Therapeutics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Akebia Therapeutics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $7.9M 2.9M 2.73
2025-06-30 $11M 2.9M 3.64

More positions owned by MPM Oncology Impact Management

Madrigal Pharmaceuticals Common (MDGL)
Cullinan Therapeutics Common (CGEM)
Avidity Biosciences Common (RNA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
PTC Therapeutics Common (PTCT)
Zai Lab Adr (ZLAB)
Syndax Pharmaceuticals Common (SNDX)
Oric Pharmaceuticals Common (ORIC)
Tarsus Pharmaceuticals Common (TARS)
Xenon Pharmaceuticals Common (XENE)
Stoke Therapeutics Common (STOK)
Dyne Therapeutics Common (DYN)
Compass Therapeutics Common (CMPX)
Alkermes Common (ALKS)

View all positions for MPM Oncology Impact Management

Top funds holding Akebia Therapeutics

BlackRock
Vanguard Group
State Street Corporation
Geode Capital Management
Morgan Stanley
Renaissance Technologies
UBS Group
Citadel Advisors
Qube Research & Technologies
MPM Oncology Impact Management
Millennium Management
Franklin Resources
Northern Trust
Affinity Asset Advisors
Invesco

View all funds holding Akebia Therapeutics